| HOME >> BIOLOGY >> TECHNOLOGY |
incentives to be issued to API employees under plans to be
established for API. The notes will bear interest at a weighted
average rate that will equate to 7.75% per annum, and will be payable
semiannually in kind in additional convertible notes. The notes are
convertible into API common stock at any time after September 30,
2009, or upon the occurrence of certain qualified transactions,
including an initial public offering of API that attains certain
valuation thresholds, a sale or disposition of API or a change in
control, sale or disposition of Angiotech while Angiotech retains a
majority interest in API.
- Tender Offers. Under the terms of the transaction, API will pay the
net proceeds from the sale of convertible notes to Angiotech. The net
proceeds will be used to consummate tender offers to repurchase
portions of Angiotech's Senior Floating Rate Notes due 2013 and its
7.75% Senior Subordinated Notes due 2014, each as tendered by holders
in response to tender offers that Angiotech expects to close
simultaneously with the transaction. As of June 30, 2008, Angiotech
had an outstanding principal balance of $575 million under the
Existing Notes.
- Remaining Angiotech Debt. Remaining debt at Angiotech upon closing
will be serviced primarily by cash flows generated from royalties
derived from the assets to be retained by Angiotech, including any
royalties received from BSC, Cook or Broncus. In addition,
Angiotech's remaining debt obligations will continue to be subject to
a guarantee by API.
- Board of Directors and Management. The Board of Directors of
Angiotech is expected to remain as comprised prior to the close of
the transaction. William Hunt
'/>"/>
| SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |